Problematic patent settlements continue to fall in number, says European Commission
This article was originally published in SRA
Executive Summary
Originator and generic manufacturers are entering into fewer "potentially problematic" settlements that violate antitrust regulations and delay market entry of generic medicines, a new monitoring exercise by the European Commission has revealed1.